Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01209819 · ClinicalTrials.gov registry record

Bone Mineral Density in Adults With Hyperphenylalaninemia

A clinical trial of Phenylketonurias, sponsored by The University of Texas Health Science Center, Houston.

Completed
Registry status
28
Enrollment target
1
Study location

NCT01209819: Completed study of Phenylketonurias, sponsored by The University of Texas Health Science Center, Houston.

NCT01209819 is a study of Phenylketonurias that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 28 participants, below the 40-participant average among 5 other Phenylketonurias trials with a reported enrollment target (30% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01209819, a study of Phenylketonurias, has completed, sponsored by The University of Texas Health Science Center, Houston.

COMPLETED
Registry status
28 participants
Enrollment target
1
Study location

Study Summary

Hyperphenylalaninemia (HPA) is a rare metabolic disorder caused by a deficiency of the enzyme phenylalanine hydroxylase (PAH). Elevated plasma levels of phenylalanine (phe) cause mental retardation, microcephaly, delayed speech, seizures, eczema, and behavior problems. Adequate control of the plasma levels of phe by a phe-restricted diet can prevent the developmental and behavioral problems. The foundation of this diet is a phe-free medical product/formula made from free amino acids. Based on longitudinal studies, it has been reported that the most benefit is attained by individuals who maintain a phe-restricted diet throughout life. Despite the obvious benefits of the diet, it has been suggested that the dietary restrictions may be associated with poor bone health in these patients. However, data supporting this has been reported in studies with small sample sizes and/or inadequate sample populations that include children. There is a paucity of data on bone health in adults with HPA. The investigators propose an observational study to describe the bone health status among adults with a diagnosis of HPA and to compare them to established normative age and gender-specific values among healthy individuals. The investigators hypothesize that adults with HPA will have lower bone density as measured by a dual x-ray absorptiometry (DXA) scan compared to the established normative values.

Conditions Studied

Study Locations (1)

Texas

  • University of Texas Health Science Center at Houston - Houston

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2010-09
Est. Completion 2012-10

What the finished NCT01209819 record still lists

NCT01209819 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 40-participant average among 5 other Phenylketonurias trials with a reported enrollment target (30% lower).

The record links to 1 condition, with Phenylketonurias appearing as the primary indexed condition, and to 0 interventions.

NCT01209819 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT01209819 about?

NCT01209819 is a clinical study titled "Bone Mineral Density in Adults With Hyperphenylalaninemia". Hyperphenylalaninemia (HPA) is a rare metabolic disorder caused by a deficiency of the enzyme phenylalanine hydroxylase (PAH). Elevated plasma levels of phenylalanine (phe) cause mental retardation, microcephaly, delayed speech, seizures, eczema, and behavior problems. Adequate control of the plasma...

What is the current status of trial NCT01209819?

This trial is currently completed. The enrollment target is 28 participants. The study started on 2010-09. Estimated completion is 2012-10.

What conditions does trial NCT01209819 study?

This clinical trial studies the following conditions: Phenylketonurias.

Who is sponsoring clinical trial NCT01209819?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01209819 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Phenylketonurias

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01209819, the US trial registry maintained by the National Library of Medicine. NCT01209819 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.